Full Press Release Details
Continuous blood glucose monitor’s preclinical data and sensor longevity modeling to be presented at major diabetes conference
Rutherford, NJ, May 02, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced two abstracts have been accepted for poster presentation at the American Diabetes Association (ADA) 84th Scientific Sessions to be held June 21-24, 2024 in Orlando, FL.
The ADA Scientific Sessions is one of the premier diabetes conferences which provides a platform for the latest advancements in diabetes research, prevention, and care. This annual meeting provides researchers and health care professionals with the unique opportunity to share ideas and learn about cutting edge technologies and breakthroughs in diabetes research and diabetes-related conditions.
“We look forward to presenting two posters discussing the preclinical animal studies and the sensor longevity simulation modeling for our Continuous Blood Glucose Monitor (CBGM)” said Paul V. Goode, PhD, CEO of Glucotrack. “We are proud to pioneer new methods for continuous glucose monitoring which will enable it to be more automatic and less intrusive to daily living and we are excited to share our compelling data with clinicians, researchers and the diabetes community attending ADA.”
The posters will be made available on the Glucotrack website following the poster session at the conference. Presentation details are as follows; times noted are Eastern time:
Category: 13-B New Technology – Glucose Monitoring and Sensing
Session Date / Time: Saturday, June 22, 12:30 PM - 1:30 PM
Poster Number: 1010-P
Title: In Vivo Evaluation of Novel Long-Term Intravascular Implantable Continuous Blood Glucose Monitor in a Chronic Ovine Model – A Glucotrack Inc. Investigation
Poster Number: 1021-P
Title: In Silico Modeling of a Long-Term Implantable Continuous Blood Glucose Monitor: A Joint Investigation by Glucotrack Inc. and TTP
For more information about Glucotrack’s CBGM, visit glucotrack.com.
About GlucoTrack, Inc.
GlucoTrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.
GlucoTrack’s CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 2+ years, no on-body wearable component and with minimal calibration. For more information, please visit http://www.glucotrack.com.
About The Technology Partnership
The Technology Partnership is an internationally respected product and technology development firm based in Cambridge, UK. For over 35 years, clients across a spectrum of industries including health tech, life science, deep tech and clean tech have trusted its deep domain expertise and enabling culture to create valuable new technology and deliver ground-breaking solutions, from first principles, through product design and manufacture to commercialisation. Please visit https://www.ttp.com/.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and GlucoTrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by the GlucoTrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect GlucoTrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect GlucoTrack’s results include, but are not limited to, the ability of GlucoTrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to GlucoTrack’s current and future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in GlucoTrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC on March 28, 2023.